Cimetidine Improves Survival in Colorectal Cancer Patients
Author Information
Author(s): Matsumoto S, Imaeda Y, Umemoto S, Kobayashi K, Suzuki H, Okamoto T
Primary Institution: Fujita Health University
Hypothesis
Does cimetidine treatment improve survival rates in colorectal cancer patients with high levels of sialyl Lewis antigens?
Conclusion
Cimetidine treatment significantly improves survival rates in colorectal cancer patients with high levels of sialyl Lewis antigens.
Supporting Evidence
- The 10-year survival rate for the cimetidine group was 84.6%, compared to 49.8% for the control group.
- Cimetidine was particularly effective in patients with high levels of sialyl Lewis antigens.
- In patients with high CSLEX expression, the survival rate was 95.5% for the cimetidine group versus 35.1% for the control group.
Takeaway
Cimetidine helps colorectal cancer patients live longer, especially if their tumors have certain markers.
Methodology
A randomized control study comparing cimetidine plus 5-FU to 5-FU alone in colorectal cancer patients.
Limitations
The study was limited by a small sample size and the need for further large-scale studies.
Participant Demographics
Patients diagnosed with colorectal cancer, aged and sex not specified.
Statistical Information
P-Value
P<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website